Literature DB >> 2039155

Molecular genetics of neurofibromatosis 2 and related tumors (acoustic neuroma and meningioma).

B Fontaine1, G A Rouleau, B R Seizinger, A G Menon, A F Jewell, R L Martuza, J F Gusella.   

Abstract

Meningioma and acoustic neuroma are among the most frequent primary tumors of the central nervous system. They usually arise as sporadic and solitary tumors. They also develop as multiple tumors in the autosomal dominant genetic disorder neurofibromatosis 2 (NF2). Molecular analysis of meningioma and acoustic neuroma revealed that loss of chromosome 22 alleles was the most frequent genetic alteration found in either sporadic or inherited cases. Subsequent studies showed that a marker in the middle of the long arm of chromosome 22 was linked to the disease in NF2 pedigrees. In this paper, the most recent findings concerning the genetics of NF2 and related tumors are reviewed, and strategy to isolate and characterize the NF2 gene is presented.

Entities:  

Mesh:

Year:  1991        PMID: 2039155     DOI: 10.1111/j.1749-6632.1991.tb37776.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

Review 1.  Molecular biology of neurological diseases.

Authors:  W J Cumming
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401

2.  Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas.

Authors:  Okay Saydam; Ozlem Senol; Tieneke B M Schaaij-Visser; Thang V Pham; Sander R Piersma; Anat O Stemmer-Rachamimov; Thomas Wurdinger; Saskia M Peerdeman; Connie R Jimenez
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

3.  Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment.

Authors:  Francesco Pepe; Pasquale Pisapia; Maria Laura Del Basso de Caro; Floriana Conticelli; Umberto Malapelle; Giancarlo Troncone; Juan Carlos Martinez
Journal:  Histol Histopathol       Date:  2019-12-24       Impact factor: 2.303

4.  MCM7 expression is a promising predictor of recurrence in patients surgically resected for meningiomas.

Authors:  Theo L Winther; Sverre H Torp
Journal:  J Neurooncol       Date:  2016-11-21       Impact factor: 4.130

5.  Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.

Authors:  Okay Saydam; Yiping Shen; Thomas Würdinger; Ozlem Senol; Elvan Boke; Marianne F James; Bakhos A Tannous; Anat O Stemmer-Rachamimov; Ming Yi; Robert M Stephens; Cornel Fraefel; James F Gusella; Anna M Krichevsky; Xandra O Breakefield
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

6.  The anti-apoptotic protein survivin can improve the prognostication of meningioma patients.

Authors:  Theo L Winther; Sverre H Torp
Journal:  PLoS One       Date:  2017-09-27       Impact factor: 3.240

7.  Whole-genome sequencing identifies new genetic alterations in meningiomas.

Authors:  Mei Tang; Heng Wei; Lu Han; Jiaojiao Deng; Yuelong Wang; Meijia Yang; Yani Tang; Gang Guo; Liangxue Zhou; Aiping Tong
Journal:  Oncotarget       Date:  2017-03-07

8.  DNA topoisomerase IIα and mitosin expression predict meningioma recurrence better than histopathological grade and MIB-1 after initial surgery.

Authors:  Theo L Winther; Sverre H Torp
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

9.  Analysis of gene expression profiling in meningioma: deregulated signaling pathways associated with meningioma and EGFL6 overexpression in benign meningioma tissue and serum.

Authors:  Xuanchun Wang; Ye Gong; Daijun Wang; Qing Xie; Mingzhe Zheng; Yu Zhou; Qin Li; Zhen Yang; Hailiang Tang; Yiming Li; Renming Hu; Xiancheng Chen; Ying Mao
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

Review 10.  Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications.

Authors:  Wenya Linda Bi; Michael Zhang; Winona W Wu; Yu Mei; Ian F Dunn
Journal:  Front Surg       Date:  2016-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.